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Monoaminergic brainstem systems have widespread projections that participate in many central pro-
cesses and, when dysregulated, contribute to a plethora of neuropsychiatric and neurodegenerative
disorders. Synapses are the foundation of these neuronal circuits, and their local dysfunction results in
global aberrations leading to pathophysiological disease states. This review focuses on the locus
coeruleus (LC) norepinephrine (NE) brainstem system and its underappreciated role in Alzheimer's
disease (AD). Amyloid beta (Ab), a peptide that accumulates aberrantly in AD has recently been impli-
cated as a modulator of neuronal excitability at the synapse. Evidence is presented showing that
disruption of the LC-NE system at a synaptic and circuit level during early stages of AD, due to conditions
such as chronic stress, can potentially lead to amyloid accumulation and contribute to the progression of
this neurodegenerative disorder. Additional factors that impact neurodegeneration include neuro-
inﬂammation, and network de-synchronization. Consequently, targeting the LC-NE system may have
signiﬁcant therapeutic potential for AD, as it may facilitate modulation of Ab production, curtail neu-
roinﬂammation, and prevent sleep and behavioral disturbances that often lead to negative patient
outcomes.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer's disease (AD) affects over 5 million Americans and
currently there is no effective treatment for this disorder. AD rep-
resents a multi-billion dollar cost to the health care system, a
burden that will continue to grow as the population ages
(Alzheimer's Association, 2015). It is a neurodegenerative disorder
originally characterized by aggregates of the amyloid beta peptide
(Ab), and hyper-phosphorylated tau as symptoms of a disease state
(Alzheimer, 1907). Today, the senile plaques composed of Ab ag-
gregates and neuroﬁbrillary tangles (NFT) composed of hyper-
phosphorylated tau are regarded as hallmark features of AD, and
together, are major histological components of AD observed in post
mortem brain tissue.
Neurodegeneration is characterized by atrophy, synaptic and
neuronal loss, and gliosis. In the clinic, AD is regarded as agy and Physiology, College of
elphia, PA 19102, USA.
Inc. This is an open access article ucontinuum that is generally divided into three phases: the pre-
symptomatic phase, mild cognitive impairment (MCI), and de-
mentia. Individuals in the pre-symptomatic phase are cognitively
normal but show some AD-related pathological changes including
abnormalities in biomarkers of Ab deposition (Jack et al., 2010).
During this phase, Ab is thought to gradually accumulate, creating
functional and structural alterations leading to MCI (Sperling et al.,
2011). Efforts by the Alzheimer's Disease Neuroimaging Initiative
(ADNI) are currently underway to identify biomarkers and other
diagnostic tools for the detection of AD-related abnormalities,
including Ab levels, during the pre-symptomatic phase (Lin and
Doraiswamy, 2014; Duygu et al., 2015). Much of the impetus for
such efforts are derived from the lack of efﬁcacy of therapeutics
targeting Ab in clinical trials, whose failure has been attributed to
the selection of participants whose amyloid burden is beyond
intervention, having already progressed toMCI (Doody et al., 2014).
MCI, is deﬁned by the onset of cognitive symptoms that do not yet
qualify as dementia, such as the inability to recall names, the
location of valuable objects and increased difﬁculty planning and
organizing (Alzheimer's Association, 2015). During this phase, in-
dividuals may also become moody or withdrawn, exhibitnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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patterns (Alzheimer's Association, 2015). Finally, dementia is
deﬁned as a loss of function produced by an array of impairments
(Jack et al., 2010), some of which are cognitive, such as loss of
awareness of recent experiences and difﬁculty communicating.
Other symptoms manifest as physical impairments, such as loss of
the ability to walk, sit, complete hygienic tasks and swallow, thus
requiring full-time assistance with daily personal care (Alzheimer's
Association, 2015). Importantly, during MCI and throughout the
progression of dementia, there are non-cognitive behavioral and
psychological symptoms of dementia (BPSD), which are important
determinants in prescribing psychotropic drugs, and contribute
signiﬁcantly to quality of life of both patients and caregivers
(McKeith and Cummings, 2005).
2. Locus coeruleus neuronal degeneration in AD
One of the earliest brain regions affected by AD is the locus
coeruleus (LC), the dorsal pontine nucleus that provides the
neurotransmitter norepinephrine (NE) throughout the entire neu-
raxis (Van Bockstaele and Valentino, 2008). Neuronal cell death in
the LC and other brain stem nuclei is awell-deﬁned characteristic of
AD pathology (Bondareff et al., 1987; Zarow et al., 2003). The
widespread projections of the LC terminate in areas important for
learning and memory such as the hippocampus, as well as in re-
gions important for the integration of the stress response such as
the amygdala and the medial prefrontal cortex. Generally, the
downstream consequences of LC degeneration are decreased levels
of NE in terminal regions (Adolfsson et al., 1979; Iversen et al.,
1983), and a compensatory upregulation of adrenergic receptors
(Kalaria et al., 1989). In contrast to other major neurodegenerative
disorders such as Parkinson's disease, patients with AD exhibited
the greatest neuronal loss in the LC. Moreover, the duration of
illness correlated signiﬁcantly with neuronal loss in the LC of AD
patients (Zarow et al., 2003). Analysis of post mortem AD brain
tissue that have quantiﬁed the magnitude of LC degeneration
indicate that cell loss reaches as high as 50% in the rostral region of
the nucleus, and further, this is correlated with a 31% reduction of
cortical NE levels (Matthews et al., 2002). Interestingly, this study
also found a positive correlation between aggressive behavior and
the magnitude of rostral LC loss, while the reduction of cortical NE
levels correlated signiﬁcantly with cognitive impairment
(Matthews et al., 2002). Thus, LC-NE system dysregulation may
contribute not only to cognitive symptoms, but also to the wide
array of non-cognitive symptoms of dementia such as agitation and
aggression (Lyketsos et al., 2000, 2002; Finkel, 2001; Mega et al.,
1996; Sink et al., 2004), which have been linked to caregiver
stress and depression (Nagaratnam et al., 1998). The neuronal cell
loss in the rostral LC has additional signiﬁcance, as this region of the
LC is known to primarily project to the cortex, a region known to
undergo highly detrimental changes during the progression of AD,
and is the earliest region in which Ab deposition is observed (Thal
et al., 2002).
Clinical data suggesting that LC degeneration plays a signiﬁcant
role in AD pathogenesis is supported by preclinical studies showing
that the degeneration of this nucleus has a signiﬁcant impact on
multiple facets of disease progression, including inﬂammation,
synaptic function, neuronal metabolism and blood brain barrier
permeability (Mravec et al., 2014). Importantly, the LC has been
implicated in Ab-induced neurotoxic insults, and studies of Ab
distribution in the clinic show the presence of Ab in major pro-
jection regions of the LC during multiple phases of Ab deposition
(Thal et al., 2002). In the next section, aspects of AD pathology will
be reviewed in the context of Ab interactions with LC neuro-
circuitry, NE and the receptors through which NE exerts its effects.3. Ab production and the inﬂuence of NE
3.1. Amyloid precursor protein (APP) processing (Fig. 1)
The production of Ab begins in the endoplasmic reticulum (ER),
where the precursor to Ab, amyloid precursor protein (APP) is
synthesized. APP is subsequently transported through the Golgi
and trans-golgi networks (TGN) where APP is post-translationally
modiﬁed by N- and O-linked glycosylation, ectodomain and cyto-
plasmic phosphorylation and tyrosine sulfonation during the pro-
cess of maturation (Haass et al., 2012). Mature APP is then delivered
to the plasma membrane via TGN-derived secretory vesicles where
it may be cleaved by a-secretase, precluding Ab formation, to
produce sAPPa (Sisodia, 1992a, 1992b). Alternatively, APP may be
re-internalized from the cell surface via clathrin-mediated endo-
cytosis. Generally, it is believed that internalization of APP, or its
retention in acidic compartments of the cell favors amyloidogenic
processing of Ab (Hong et al., 2014).
The notion that the subcellular localization of APP determines
its participation in two divergent processing pathways has signif-
icant implications for AD and has become essential to our under-
standing of Ab production. As such, understanding what drives APP
to either pathway has become the subject of intense investigation
and has highlighted the importance of synaptic activation in the
etiology of Ab production. For example, it has been demonstrated
that increased synaptic activity results in increased production and
secretion of Ab into the extracellular space, as measured by levels of
Ab in interstitial ﬂuid (Cirrito et al., 2003), and further, that this is
an endocytosis-dependent process (Cirrito et al., 2008). The pro-
posed model by which synaptic activity and endocytosis contribute
to Ab generation is predicated on the idea that intracellular calcium
inﬂux triggered by the depolarization of the cell results in synaptic
vesicle release, and concomitant increases in synaptic membrane
recycling via clathrin-mediated endocytosis. The increased recy-
cling of membranous components results in greater internalization
of APP which then serves as a substrate of b- and g-secretases
thereby enhancing Ab production (Cirrito et al., 2008).
Investigation of the localization of APP, BACE-1 and g-secretases
at the synapse have revealed their presence in synaptic vesicles of
hippocampal primary neuronal cultures (Groemer et al., 2011), and
in catecholaminergic chromafﬁn cells in vitro (Toneff et al., 2013).
Chromafﬁn cells have been utilized to investigate the regulated
secretion of neurotransmitters from large dense core vesicles
(LDCV) (Toneff et al., 2013), the primary site of neuropeptide syn-
thesis and also a site of NE synthesis (Wang and ebrary Inc, 2008).
Toneff and colleagues demonstrated that when chromafﬁn cells are
stimulated by KCl depolarization, or forskolin, Ab was co-secreted
with other neuropeptides and catecholamine neurotransmitters,
including NE. When LDCVS were isolated and examined using
western blot analysis, BACE-1, g-secretase, APP and Ab are present,
indicating that the LDCVs may be a site of Ab synthesis and release
(Fig. 1). Interestingly, a recent study of post mortem AD brain tissue
revealed that the chromogranin peptides unique to LDCVs are
dysregulated in AD. Particularly, Chromogranin A was shown to be
elevated, within senile plaques, and highly associated with
dystrophic neurites and activated glial cells (Lassmann et al., 1992;
Lechner et al., 2004). Thus studying the mechanisms of LDCV
release, and their synaptic components such as the chromogranin
peptides within noradrenergic neurons in the brain may be an area
of future research.
3.2. Adrenergic receptor inﬂuence on Ab production
Extensive research on the involvement of GPCRs in APP pro-
cessing and Ab production have revealed that various GPCRs may
Fig. 1. Trafﬁcking Route of APP, a-secretase, BACE1 and g-secretase. Full length APP is synthesized in the endoplasmic reticulum and subsequently transported through the Golgi,
and trans-Golgi network (TGN) where APP undergoes post-translational modiﬁcations such as glycosylation and phosphorylation during maturation. Full length APP can be
transported to the cell surface in TGN-derived secretory vesicles, where APP may be cleaved by a-secretase present within the plasma membrane to produce sAPPa, or re-
internalized via clathrin mediated endocytosis. Typically elevated retention within the endosome leads to increased production of the toxic amyloid beta by the b-secretase,
BACE1, which is localized to and optimally cleaves in the acidic conditions of the endosome. BACE1 cleaves APP into the sAPPb and C99 fragments, and the C99 fragment is then
cleaved again by the gamma secretase also present in the endosome, to produce the amyloid beta peptide that is known to aggregate and become neurotoxic. Subsequently, Abmay
be degraded in the lysosome, or participate in the secretory pathway, where Ab will be released into the extracellular space. Another potential site of Ab production, still under
investigation, are the large dense core vesicles (LDCVs). APP, b- and g-secretases have been localized to LDCVs. Initial formation of LDCVs occurs at the TGN; following neuropeptide
synthesis in the cell body, condensation of LDCV contents and maturation is facilitated by chromogranin peptides that reside within the LDCVs. LDCVs may be released at the soma,
or undergo anterograde transport to terminal regions where they may be released away from active zones (Wang and ebrary Inc, 2008).
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activity of the secretases that cleave APP or inﬂuence its subcellular
localization. In the context of this review, we will speciﬁcally focus
on the role of the b2 and a2 adrenergic receptors. Adrenergic re-
ceptors in the post mortem AD brain have been investigated; while
a2AR density is unaltered (Matthews et al., 2002), b2AR density is
elevated in the frontal cortex and hippocampus (Kalaria et al.,
1989), and polymorphisms in the gene encoding the b2AR are
associated with an increased risk of developing sporadic late onset
AD (Yu et al., 2008). These ﬁndings have important implications for
AD, as b2 and a2AR are localized to terminal regions of the LC and
have a direct inﬂuence on synaptic transmission and the APP pro-
cessing machinery residing at the synapse (Fig. 2). Moreover, these
receptors have been implicated in the production and secretion of
Ab.
Electron microscopy studies have localized the b2 adrenergic
receptor (b2AR) on dendritic spines of pyramidal neurons of the
PFC and on GABAergic interneurons (Aoki et al., 1998), as well as on
glia, where they may reduce the uptake of glutamate and regulate
glucose availability (Fillenz and Lowry, 1998). Generally bARs are
positively coupled to the Gs/cAMP second messenger system and
are predominantly localized post-synaptically; however, reports
have also identiﬁed pre-synaptic bARs that facilitate NE release
(Berridge andWaterhouse, 2003). One proposedmechanism for the
regulation of Ab production by b2-AR is via the joint endocytosis of
b2 and APP from the plasma membrane following stimulation,
which increases the co-localization and availability of APP to act as
a substrate for g-secretase in the endosomal compartment (Ni et al.,
2006). It has also been postulated that b2AR is able to modulate Ab
production via its association with b-arrestin2, which physicallyinteracts with the a1A subunit of the g-secretase complex, resulting
in increased catalytic activity of the complex (Thathiah et al., 2013).
Further support for b2AR regulation of Ab production is derived
from studies using b2 antagonists, which show diminished levels of
Ab40 and Ab42 in a transgenic animal model after chronic treat-
ment (Ni et al., 2006). Thus b2AR stimulation appears to promote
Ab production at noradrenergic synapses and transmission at these
synapses is controlled by afferents from the LC, therefore dysre-
gulation of the LC induced by stress may contribute to increased Ab
production during prodromal or early stages of the disease (Fig. 2).
Following this logic, it may be hypothesized that subsequent
upregulation of b2-ARs during the degeneration of the LC may
contribute to Ab deposition to a lesser extent due to decreased
levels of NE. This is consistent with biomarkers of AD progression,
which show that levels of Ab gradually increase as early as 20 years
prior to the onset of symptoms, and plateau during neuro-
degeneration (Jack et al., 2010).
The a2 adrenergic receptors (a2AR) are coupled to Gi/cAMP
systems and are predominantly localized presynaptically, acting as
autoreceptors that regulate NE synthesis and release (Berridge and
Waterhouse, 2003). Early studies exploring catecholamine neuro-
transmitters and receptors in age-related cognitive disorders
identiﬁed a2 adrenergic receptors as contributors to cognitive
decline in the prefrontal cortex (Arnsten and Goldman-Rakic,
1985). More recently, the a2aAR has been implicated in the regu-
lation of APP processing and subsequent Ab production and
secretion via the endocytic and secretory pathways (Chen et al.,
2014). This study revealed that through an interaction with
SorLA, a sorting-related protein known to retrogradely transport
APP from the endosome to the Golgi, the a2AR promotes the
Fig. 2. Adrenergic Receptor Inﬂuence on Ab production. The b2 adrenergic receptor is a Gs coupled receptor that may inﬂuence Ab production in two ways. First, APP may be
internalized with b2 following periods of prolonged stimulation, therefore allowing APP to act as a substrate for b- and g-secretases in the endosome. Second, b2 may interact with
the b-arrestin 2 protein that directly interacts with the a-1A subunit of g-secretase, increasing its catalytic activity. The a-2A receptor is a Gi coupled receptor that inﬂuences Ab
production by disrupting the interaction of APP with SorLA, a retromer that protects APP from proteolytic cleavage.
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genic mice. Based on this evidence it is clear that the b2 and a2aARs
play a role in the modulation of Ab production and secretion
(Fig. 2). Importantly, this evidence may suggest that dysregulation
of the LC-NE system in early stages of Alzheimer's contributes to
increased Ab accumulation in LC terminal regions. Thus, a phar-
macological intervention aimed toward controlling adrenergic re-
ceptor inﬂuence on Ab production and secretion in early stages of
AD may delay subsequent degeneration. Such a therapeutic strat-
egy may not be as effective in later stages of the disease when
neurodegeneration of the LC results in decreased NE levels, and
consequent decreased stimulation of adrenergic receptors.
4. Physiological and pathological role of Ab in synaptic
transmission and network synchronization
Multiple lines of evidence now support a physiological role for
endogenous Ab in the central nervous system. Previously unap-
preciated, it is now established that there are normal levels of
endogenous Ab in the low picomolar range in both human and
animals CNS (Cirrito et al., 2003; Brody et al., 2008). Studies
focusing on endogenous Ab have demonstrated that its production
and secretion is a tightly regulated process that occurs at the syn-
apse following changes in synaptic activity (Cirrito et al., 2005) in a
clathrin-mediated endocytosis-dependent manner (Cirrito et al.,
2008). Using a specialized expression system to acutely deliver
APP in organotypic hippocampal slices, Kamenetz et al. (Kamenetz
et al., 2003) were able to determine the effects of APP over-
expression on synaptic transmission and the reciprocal effects of
synaptic transmission on APP processing. These studiesdemonstrated for the ﬁrst time that increased neuronal activity
increased Ab production via increases in b-secretase activity, and
that the resulting elevated levels of Ab decreased synaptic function,
suggesting a potential role for Ab in a postsynaptic negative feed-
back loop mechanism (Kamenetz et al., 2003). The aberrant
elevation of Ab in conditions such as ADwould be expected to over-
activate the negative feedback arm of this mechanism, decreasing
excitatory transmission (Palop and Mucke, 2010). Importantly, too
high or too low concentrations of Ab have been shown to impair
synaptic transmission. Picomolar concentrations of Ab signiﬁcantly
enhance synaptic transmission, whereas nanomolar concentrations
cause synaptic depression. Thus Ab may be part of a modulatory
feedback mechanism that controls neuronal excitability (Palop and
Mucke, 2010). While the details of Ab interaction are a subject of
intense ongoing investigation, some studies have proposed mech-
anisms bywhich Abmay act pre- and post-synaptically tomodulate
neuronal activity. Evidence that Ab acts as a positive regulator of
synaptic activity at the presynaptic level has been demonstrated
(Abramov et al., 2009); speciﬁcally, Ab may act directly on pre-
synaptic a7-nAChR to increase presynaptic Ca2þ and Ab secretion
(Palop and Mucke, 2010). At the post-synaptic level, Ab has been
shown to facilitate long term depression (LTD), and suppress long
term potentiation (LTP) through the NMDA receptor signaling axis.
A number of studies have investigated these effects, demonstrating
that Ab blocks the uptake of glutamate (Li et al., 2009), promoting
spill-over of glutamate at the synapse, and engaging the peri-
synaptic NMDA receptors that have an important role in initiating
LTD (Talantova et al., 2013; Liu et al., 2004). Other studies have
suggested that these effects may be mediated by NMDA receptor
desensitization, internalization, and subsequent collapse of
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induced internalization and degradation of the b2-AR (Wang et al.,
2011) suggests that mechanisms of Ab interaction may be gener-
alized to other signaling systems, and may be an important area for
future research.
With mounting evidence for the role of Ab in synaptic modu-
lation, a new perspective on the downstream consequences of Ab
dysregulation has emerged. In this framework, the dysregulation of
Ab results in aberrant network synchronization that globally dis-
rupts cognitive function and normal brain processes such as the
balance between inhibitory and excitatory tone (Palop and Mucke,
2010). In particular, disruptions to the GABAergic and glutamatergic
systems appear to contribute largely to the disruption of normal
network synchronization. This hypothesis is supported by evidence
that Ab is predominantly distributed along networks with aberrant
neuronal activity in AD patients (Buckner et al., 2005), and in-
creases in Ab may cause epilepsy and cognitive deﬁcits (Palop and
Mucke, 2009). Further, AD is associated with increased incidence of
seizures independently of disease stage, a history of infrequent
seizures is common in sporadic AD patients, and more discernible
epilepsy is evident in familial early-onset AD [Reviewed in Palop
and Mucke, 2009]. Importantly, increased neuronal activity and
epilepsy can increase the production, release, and/or accumulation
of Ab (Mackenzie and Miller, 1994). In vivo models have also
demonstrated abnormal EEG activity associated with spontaneous
epileptiform activity in hAPPmice (Verret et al., 2012). Alteration in
neurological functions in AD models, reﬂected in abnormal oscil-
latory rhythms or network synchronization are likely a result of
changes in activity-regulated gene expression, complex signaling
systems such as mitogen activated protein kinases (MAPK), cyclin-
dependent kinase 5 (cdk-5), tyrosine kinases, and alterations in
synaptic vesicle release and recycling (Palop et al., 2006). EEG
studies in AD patients have revealed decreases in alpha, beta and
gamma frequency bands (Koenig et al., 2005). Of particular interest
are alterations to the gamma frequency band, which are thought to
be important for attention, and memory storage and retrievalFig. 3. Model of proposed contribution of LC-NE Dysregulation in Alzheimer's disease. Our c
(a), leads to global aberrant LC activity in its widespread projection areas (A). With increased
Ab production in synaptic vesicles such as the LDCVs (B). Increased Ab production and secret
processing (b). Further, the ability of NE to undergo volume transmission, engaging extras
niﬁcant implications for the microenvironment (B, C). Finally, following a prolonged peri
downstream loss of inﬂammatory modulation results in the detrimental activation of glial ce(Jensen et al., 2007). The activation of GABAA receptors is thought
to contribute to underlying mechanisms promoting persistent
gamma-frequency oscillations (Traub et al., 2003). Recent studies
have demonstrated the ability of selective norepinephrine reuptake
inhibitors (SNRIs), reboxetine and desipramine, to enhance gamma
activity of the septo-hippocampal system (Hajos et al., 2003). In
support of this, evidence in the literature suggests a role for NE
stimulation of adrenoreceptors in modulating GABAergic inhibitory
systems in the brain. These studies demonstrate the ability of NE to
promote the induction of synaptic plasticity by GABAergic inhibi-
tion, as well as the ability of NE to enhance the frequency and
amplitude of GABAergic inhibitory post synaptic currents and
potentiate GABAergic processes (Waterhouse et al., 1980), effects
which may be exerted differentially depending on the region of the
brain and the receptor subtype activated (Tully and Bolshakov,
2010). Consequently, a reduction in LC-NE activity and NE levels
could result in a decrease in GABAergic inhibitory activity leading to
phenomenon such as spontaneous epileptiform activity, and ab-
normalities in gamma oscillations. Thus, multiple lines of evidence
suggest that targeting the NE system via the utility of SNRIs in later
stages of ADmay provide support for GABAergic inhibitory systems
while also potentially stabilizing gamma frequency activity.
5. Proposed contribution of stress and LC-NE system to Ab
modulation and AD pathology
The LC circuit has not yet been studied in the context of network
de-synchronization resulting from aberrant Ab deposition in the LC
and its terminal regions. Thus, an outstanding question is whether
aberrant LC activation and subsequent increased Ab in projection
areas of the LC provides impetus for global dysfunction of LC cir-
cuitry, initially in the form of aberrant, over-activation and subse-
quently in the retraction of dendritic spines, and degeneration of its
widespread afferents. Fig. 3 illustrates our working model, and is
based on the hypothesis that chronic exposure to stress may
facilitate aberrant activity of the LC system (Fig. 3a). Consequently,urrent working model proposes that aberrant activation of the LC at the synaptic level
synaptic activity, increased transmission of NE may occur concomitantly with increased
ion may result from the described mechanisms of adrenergic receptor inﬂuence on APP
ynaptic mechanisms of transmission on neighboring neuronal and glial cells, has sig-
od of Ab accumulation, cortical thinning, decreased noradrenergic transmission, and
lls, and decreased dendritic spine density, and potentially network de-synchronization.
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where adrenergic receptors are present and may contribute to the
production of Ab (Fig. 3b). It may be further hypothesized that Ab
dysregulation and resulting network desynchronization contribute
to LC degeneration. Thus, the initial accumulation of Ab resulting
from stress would be evident prior to degeneration of the LC, and
subsequent loss of noradrenergic tone in widespread terminal re-
gions of the LC may exacerbate other aspects of AD pathology
(Fig. 3c). While there is still much to be explored, there is sub-
stantial evidence that the dysregulation of this system may have
detrimental effects in the AD brain. The LC-NE system is uniquely
positioned, as it is involved in multiple processes involved in
memory and cognition, may be stimulated by external factors such
as stress, and targets global projection areas, allowing for large-
scale changes in the brain environment. Of particular interest are
the afferents expressing corticotropin releasing factor (CRF) from
the central nucleus of the amygdala (CeA), which are thought to
activate the LC in response to environmental stressors (Valentino
et al., 1983, 1992a; Van Bockstaele et al., 1998), and the hypo-
cretin afferents of the lateral hypothalamus to the LC, which have
an important role in mediating transitions of sleep to wake and
promoting overall wakefulness (Mignot, 2001; Peyron et al., 1998).
The importance of these afferents is based on their ability to
modulate LC function, thereby inﬂuencing the actions of NE on
widespread terminal regions. Further, dysregulation of Ab peptide
synthesis and release at the synaptic intersection of these regions
and the LC may contribute to aberrant LC activation and promote
global network de-synchronization of its afferents.
6. LC-NE stress integrative circuitry and Ab
A number of clinical studies have suggested an important role
for stress and stress-related neurocircuitry in AD patients. The
observations that led to this assertion include elevated baseline
cortisol levels in AD patients that correlate with changes in per-
formance on the ADAS-Cog exam (Weiner et al., 1997), more rapidly
increasing symptoms of dementia and a more rapid decline in
performance on neuropsychological tests when compared to non-
demented controls (Csernansky et al., 2006). Clinical studies
show that patients with a high level of distress are 2.7 times more
likely to develop AD, and that this trait is also associated with
accelerated progression of the disease (Wilson et al., 2003, 2005).
Reports of abnormalities of several levels of the HPA axis in patients
with AD have been reported, suggesting increased central drive of
this critical physiological and neurological axis in responding to
stressful stimuli (Rasmuson et al., 2001). For example, patients with
AD have been reported to have increased production of glucocor-
ticoids (GC) and decreased sensitivity to GC negative feedback, as
well as downregulated ACTH responses to corticotropin releasing
hormone (CRH) (Rasmuson et al., 2001). Clinical ﬁndings are sup-
ported by preclinical studies that have demonstrated increased
central drive of the stress system and decreased GC feedback
contribute to cognitive dysfunction in models of AD (Elgh et al.,
2006; Hebda-Bauer et al., 2013). Interestingly, in the Tg2576
model of AD, cognitive decline was rescued following administra-
tion of the glucocorticoid receptor antagonist RU486, which may
represent a novel therapeutic strategy (Lante et al., 2015).
The LC-NE system is often described as a stress integrative cir-
cuit based on the fact that the LC responds, in parallel with pe-
ripheral stress responses, to a vast array of stressful stimuli, both
cognitive and physical (Van Bockstaele and Valentino, 2008). This
has been demonstrated in microdialysis studies investigating the
effects of restraint, tail shock, auditory and hypotensive stressors on
extracellular levels of NE in terminal regions of the LC (Abercrombie
et al., 1988; Britton et al., 1992). In agreement with these ﬁndingsare studies investigating other endpoints of LC-NE system activa-
tion including expression of tyrosine hydroxylase mRNA and c-fos
mRNA expression (Beck and Fibiger, 1995; Bonaz and Tache, 1994;
Campeau and Watson, 1997; Chan and Sawchenko, 1995; Chang
et al., 2000; Makino et al., 2002). Corticotropin releasing factor
(CRF) is believed to mediate stress-induced LC activation, and this
hypothesis is supported by anatomical evidence that CRF-
immunoreactive ﬁbers densely innervate the peri-coerulear re-
gions into which the locus coeruleus dendrites extend (Valentino
et al., 1992a). Further, high resolution electron microscopy anal-
ysis of this region identiﬁed asymmetrical (excitatory) synaptic
specializations between CRF-immunoreactive axon terminals and
LC dendrites, suggesting that CRF afferents to this region directly
control LC neuronal excitability and activity (Van Bockstaele and
Valentino, 2008). Importantly, the LC receives CRF input from
multiple regions, including the central nucleus of the amygdala
(CeA), bed nucleus stria terminalis, paraventricular nucleus of the
hypothalamus (PVN), Barrington's nucleus, and the nucleus para-
gigantocellularis (Reyes et al., 2005; Valentino et al., 1992a). Under
normal physiological conditions, following glucocorticoid synthesis
and release from the adrenal cortex in response to a stressful
stimulus, glucocorticoids participate in a negative feedback loop
that suppresses the activity of the PVN, thus having downstream
consequences for CRF release in the LC. Conditions such as AD, in
which corticosteroid receptors, or other aspects of the corticoste-
roid regulatory feedback system are dysregulated, represent cir-
cumstances in which LC activity would be predicted to be tonically
elevated (Van Bockstaele and Valentino, 2008). The signiﬁcance of
this response becomes more pronounced when downstream con-
sequences of LC and stress related circuit dysregulation are
considered in the context of Ab deposition and Alzheimer's pa-
thology. The following sectionwill explore how ampliﬁcation of the
stress system disrupts normal neuronal processes on a circuit level
and affects cellular and molecular processes at the synapse, pro-
moting Ab production and accumulation.
7. Effects of stress and glucocorticoid production on Ab
deposition
The reported clinical ﬁndings regarding the involvement of the
stress system in AD pathogenesis are supplemented by preclinical
studies that have further investigated aspects of the stress response
system that may be involved in this dysregulation. It has been
demonstrated in transgenic mouse models of AD that stress exac-
erbates Ab production (Green et al., 2006; Jeong et al., 2006). For
example, isolation stress increases corticosterone and glucocorti-
coid receptor levels in the hippocampus and cortex of Tg2576 mice
in conjunction with increased Ab plaque deposition. A strong cor-
relation was identiﬁed between plaque deposition and plasma
corticosterone levels in the cortex of these transgenic mice (Dong
et al., 2008). Earlier studies from this laboratory showed that
Tg2576 mice have increased Ab deposition, decreased capacity for
neurogenesis in the hippocampus, and impaired contextual mem-
ory following isolation stress (Dong et al., 2004). Other groups have
shown that stress and excessive GC promotes the production of Ab
by shifting APP processing towards the amyloidogenic pathway in
normal, middle aged rats (Catania et al., 2009). This study utilized
multiple techniques to augment the stress system, including a
chronic stress paradigm, exogenous GC administration, and exog-
enous Ab administration, to demonstrate that increased production
of the C-terminal fragment (C99) that is cleaved to form Ab results
from activating the stress system, and further, exacerbates spatial
memory deﬁcits induced by Ab.
The detrimental effects of stress-induced CRF activation in the
context of AD have also been explored in preclinical models. While
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not been conducted, it has been demonstrated that when other
regions densely populated with CRF receptors such as the hippo-
campus are directly infused with CRF there is a resultant increase in
interstitial ﬂuid Ab levels in a dose- and neuronal activity depen-
dent manner (Kang et al., 2007). CRF induced responses are
mediated by G-protein coupled CRF receptor1 (CRFR1) and CRF
receptor 2 (CRFR2) (Bale and Vale, 2004). The major stress receptor,
CRFR1, modulates cellular activity in many AD-relevant brain areas
and has been demonstrated to impact both tau phosphorylation
and amyloid b pathways (Campbell et al., 2015a). It has been
demonstrated that isolation stress increases CRFR1 expression in
conjunctionwith increases in Ab levels and Ab plaque deposition in
the Tg2576 model of AD (Dong et al., 2008). Meanwhile, studies
using a transgenic mouse line null for CRFR1 with PSAPP double
transgenicmutations show signiﬁcantly reduced Ab 40, 42 peptides
and decreased APPb-CTFs in multiple brain regions compared to
PSAPP counterparts as measured by ELISA (Campbell et al., 2015a).
While a complete discussion of the effect of stress and CRFR1
signaling on the phosphorylation of tau are beyond the scope of this
review, there is substantial evidence to support the involvement of
the CRF axis of the stress system in AD pathology, and in relation to
the LC. Brieﬂy, studies utilizing mice null for CRFR1 have found that
CRFR1 deletion blocks the stress induced upregulation of GSK-3b
and JNK, kinases responsible for phosphorylating tau at AD relevant
sites. Consequently, CRFR1 deletion results in decreased phos-
phorylation of tau in the hippocampus compared to stressed
wildtype controls (Rissman et al., 2007). Further studies by this
group have established that conditions of chronic, repeated stress
in wildtype animals result in increased phosphorylation of tau, a
portion of which is observed in a detergent-soluble cellular frac-
tion, reﬂecting a possible pre-pathogenic form. Importantly, these
effects were blocked when CRFR1/ mice were subjected to the
same chronic stress paradigms (Rissman et al., 2012). Studies uti-
lizing CRF overexpressing mice demonstrate increased phosphor-
ylation of tau at the S202/204, and S296/404 AD relevant sites,
effects which are blocked following administration of the CRFR1-
antagonist R121919 (Campbell et al., 2015b). Interestingly, recent
reclassiﬁcation of staging by Braak and colleagues proposes that tau
dysregulation begins in the LC, and subsequently spreads trans-
ynaptically to other regions of the brain (Braak and Del Tredici,
2011). Thus, this evidence elevates the LC as a pivotal point of
intersection for stress-induced aberrant activation of the CRFR1
signaling axis, resulting in the dysregulation of tau-
phosphorylation and Ab production and accumulation. The LC is a
critical integration center for the stress response and is heavily
populated with CRFR1; however the consequences of stress on LC
circuitry in the context of tau-P and Ab primary components of AD
have not been elucidated and represent a signiﬁcant gap in our
knowledge that merits further exploration.
Exposure to severe or chronic stress results in the loss of den-
dritic spines and by extension, synapses, and has been attributed to
actin cytoskeleton collapse downstream of CRFR1 within hippo-
campal excitatory synapse spine heads (Chen et al., 2012). In line
with these results, triple transgenic mice that overexpress CRF and
human APPb with a conditional promoter speciﬁc for forebrain
expression show increases in soluble Ab and Ab plaques with
consequent decreases in dendritic branching and dendritic spine
density in pyramidal neurons in layer IV of the frontal cortex and
CA1 of the hippocampus (Dong et al., 2012). Studies utilizing a
hAPPSL/hTau transgenic mouse line have demonstrated a syner-
gistic relationship of Ab and dysregulation of tau phosphorylation.
This synergy is evident in 50% increased tau accumulation, partic-
ularly of insoluble Tau, compared to transgenic models of hTau
alone. Additionally, this model shows no further alterations in hAPPlevels, compared to single transgenic models of hAPP alone
(Chabrier et al., 2014). Investigators also observed an upregulation
of the Fyn kinase, a protein tyrosine kinase associated with both Ab
and tau-P disruption (Roberson et al., 2011), in this mouse model
(Chabrier et al., 2014). The upregulation of Fyn occurred concur-
rently with a signiﬁcant decrease of the post synaptic marker PSD-
95 and reduction in mushroom spines, which has been correlated
with cognitive decline in several models of AD pathology (Dickstein
et al., 2010; Perez-Cruz et al., 2011). Importantly, these alterations
were not observed in either single transgenic mouse line alone.
Thus, these studies have suggested that humanwild-type tau alone
becomes hyperphosphorylated with age, but the presence of Ab
facilitates accumulation of both soluble and insoluble tau (Chabrier
et al., 2014). The cellular and molecular alterations summarized
here indicate that increased central drive of stress systems promote
the production of Ab and the phosphorylation of tau, compromising
the integrity of synaptic connections, and ultimately contribute to
synaptic loss in an Ab-dependent synergistic fashion.
8. LC-NE system and memory and learning circuitry
Given the evidence presented above from both clinical and
preclinical studies, it is important to understand the neuroana-
tomical and pharmacological processes that may connect the stress
system with Ab production and memory impairment. The
involvement of the noradrenergic system in learning and memory
processes is a controversial topic, as various methods to interfere
with adrenergic signaling, focusing on acquisition, consolidation,
retrieval and reconsolidation of memory have yielded conﬂicting
results (Murchison et al., 2004). This observation led Murchinson
and colleagues to use a genetically modiﬁed mouse line null for the
norepinephrine synthesizing enzyme, dopamine-b-hydroxylase
(DbH) to explore multiple dimensions of learning in memory tasks.
Further, the use of a synthetic norepinephrine precursor, L-threo-
3,4-dihydroxyphenylserine (L-DOPS) injection at speciﬁc times
during training and testing allowed for the examination of the role
of NE during different phases of the learning and memory pro-
cesses. The results of this study yielded the important ﬁnding that
norepinephrine is critical for the retrieval of intermediate-term
contextual and spatial memories in the hippocampus through b1-
AR signaling (Murchison et al., 2004). Other regions implicated in
noradrenergic mediation of memory processes include the amyg-
dala and the prefrontal cortex, which are also heavily involved in
the integration of the stress response. The basolateral amygdala
(BLA) receives dense innervation from the LC and NE increases in
the BLA in response to stress. Further, noradrenergic inﬂuence in
the BLA has been shown to enhancememory consolidation induced
by hippocampal (Roozendaal et al., 1999) and mPFC (Roozendaal
et al., 2004) glucocorticoid receptor activation, an effect that is
dependent on b2 adrenergic receptor activation in the BLA
(O'Donnell et al., 2012). Moreover, noradrenergic inﬂuence of the
BLA has been shown to have an important but not exclusive role in
working memory processes of the PFC (Roozendaal et al., 2004). It
has been demonstrated both in vitro and in vivo that Ab42 induces
the internalization and degradation of b2AR in prefrontal cortical
neurons (Wang et al., 2011), an important ﬁnding considering the
recent evidence that stimulation of b2ARs have beneﬁcial effects on
working memory in young and aging animals (Ramos and Arnsten,
2007). Further, this study shows that binding of Ab to the b2AR
leads to desensitization, and subsequent attenuation of cAMP, PKA
signaling and phosphorylation of glutamate receptor subunits and
subsequent mini EPSCs (Wang et al., 2011). This is particularly
signiﬁcant as studies have demonstrated that restoration of cAMP
signaling using rolipram in mouse models of AD have demon-
strated the ability to reverse long-term dendritic spine loss (Smith
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the hippocampus, amygdala, and PFC (Ramos and Arnsten, 2007),
and their participation in Ab production, cAMP signaling, and po-
tential modulation of dendritic spine density, represent additional
mechanisms by which LC-NE dysregulation may contribute to AD
pathogenesis.
9. Convergence of peptide interactions on the LC-NE system
and inﬂuence on Ab
The LC is known to play a physiological role in promoting
wakefulness and attention. Afferents to the LC include the hypo-
cretin (orexin) containing neurons of the hypothalamus, whose
stimulation of hypocretin receptors present in the LC, results in
increased discharge of LC neurons (Horvath et al., 1999). Under
normal physiological conditions, orexin facilitates the transition
from sleep to wakefulness at least in part, by exciting the LC,
resulting in the synthesis and release of NE (Carter et al., 2012).
Studies of AD post mortem brain tissue and ventricular cerebro-
spinal ﬂuid indicate a loss of orexinergic signaling, reﬂected by a
40% decreased cell number, and 14% lower CSF hypocretin-1 levels
(Fronczek et al., 2012). This is consistent with clinical reports of
sleep disturbances in AD patients (Tractenberg et al., 2003), which
correlate with severity of dementia (Mirmiran et al., 1992), and are
often the primary reason for institutionalization (Pollak and Perlick,
1991; Vitiello et al., 1990; Vitiello and Borson, 2001). Interestingly,
the hypocretin-orexin system has been implicated in Ab generation
and modulation. Studies of APP transgenic models show that pe-
riods of wakefulness initiated by the orexin system, are correlated
with greater levels of Ab in the interstitial ﬂuid of the hippocampus
than during sleep, an effect that is dependent on orexin signaling
through orexinergic receptors (Kang et al., 2009). The mechanism
by which orexin receptors promote Ab synthesis was found to be
independent of cAMP signaling, and requires further investigation
(Kang et al., 2009). In line with these results, preclinical studies
utilizing two different models of AD (APPswe and APPswe/Ps1dE9)
demonstrate that sleep deprivation increased levels of Ab and
accelerated plaque formation compared to controls. Conversely,
enhanced sleep, achieved via administration of an orexin receptor
antagonist decreased Ab plaque formation and deposition in these
models (Ju et al., 2014; Roh et al., 2014). The orexin system has not
been studied in the context of aberrant network activity due to Ab
dysregulation; however, this may be an important area for future
research. Importantly, the LC is one of the regions most densely
populated with orexinergic receptors (Horvath et al., 1999). Thus,
the inﬂuence of orexin receptors on Ab production and accumula-
tion in the LC may contribute to its dysregulation. Further, it has
been hypothesized that increased NE stimulation of b2AR in pro-
jection areas of the LC following orexinergic input result in
increased Ab production via mechanisms discussed above (Cheng
et al., 2014). This concept supports the idea that dysregulation of
LC functioning has signiﬁcant consequences for the widespread
projection areas in which adrenergic receptors reside and mediate
the effects of noradrenergic transmission. The evidence presented
here suggests a role for the orexin system in promoting the gen-
eration of Ab, and while the precise mechanisms by which this
occurs is not well understood, it has been suggested that the LC-NE
system plays an important role in mediating these effects (Cheng
et al., 2014). Thus restoration of normal noradrenergic trans-
mission via the modulation of adrenergic receptors may provide
additional beneﬁt in treating the AD patient population by modu-
lating responsivity to orexinergic input that promote wakefulness
via NE transmission. Additionally, clinical studies have provided
evidence for the link between stress-induced sleep disturbances
and hyperarousal (Drake et al., 2004), a connection that is furthervalidated by evidence that sleep deprivation increases CRF levels
and CRF receptor binding (Fadda and Fratta, 1997). Thus, further
research investigating peptidergic interactions inﬂuence on
arousal, LC activation and Ab productionmay provide insight on the
convergence of these factors in AD pathology.
10. Female vulnerability in AD
In the clinic, multiple lines of evidence have suggested that men
and women are affected by dementia differently. Of the 5.1 million
Americans suffering from AD, approximately two-thirds are
women (Alzheimer's Association, 2015). Longitudinal studies
investigating the rate of cortical thinning in men and women with
AD show that over a ﬁve year time period, women with AD display
more rapid thinning in the left prefrontal cortex, bilateral medial
frontal cortex, bilateral tempo-parietal associative cortex, and
bilateral temporal lobe compared to men with AD. Importantly,
there were no signiﬁcant differences in baseline cortical thickness
between the men and women examinees (Cho et al., 2013). Similar
studies have shown signiﬁcant gender differences in cognitive and
functional decline (Lin and Doraiswamy, 2014), with some report-
ing that the memory impairment in women may progress at twice
the rate of men (Seshadri et al., 1997). Recent studies by the ADNI
have further demonstrated that the gender differences between
men and women affected by AD are reﬂected in Ab dysregulation;
at every stage women had more amyloid plaques than men, and
women were shown to have greater levels of amyloid load
regardless of ApoE-ε4 carrier status. Interestingly, previous in vitro
studies have demonstrated the ability of physiological levels of
estrogen to modulate APP processing, promoting the production of
sAPPa, precluding the production of Ab in primary neuronal mouse
and human cultures (Xu et al., 1998). In line with these results,
postmenopausal estrogen replacement therapy has been associated
with decreased risk of AD (Tang et al., 1996). While clinical trials
examining the efﬁcacy of estrogen replacement therapy in slowing
AD progression inwomenproved to be unsuccessful, participants of
the study had mild to moderate AD (Mulnard et al., 2000), condi-
tions in which Ab is expected to be elevated and beyond inter-
vention. Given the recent evidence that the stress response plays a
role in AD pathology, and that there are differences in stress re-
sponses between males and females (Goldstein et al., 2010;
Bangasser et al., 2010), one study investigated the cortisol levels
of women with AD. This study found that women with mild to
moderate AD have signiﬁcantly increased levels of cortisol pro-
duction (Rasmuson et al., 2001).
Preclinical data in mouse models of AD support the notion that
the disease affects males and females differently. For example, a
study utilizing a double mutant APP/PS1 transgenic mouse line
reported that female mice had signiﬁcantly greater Ab load than
males at all ages (Howlett et al., 2004). Other lines of preclinical
research have suggested a model of sex-biased stress signaling, in
which neurochemical (Curtis et al., 2006), morphological
(Bangasser et al., 2011) and molecular (Bangasser et al., 2010)
differences between males and females in CRF innervation and
signaling to the LC render females more susceptible to stress-
related psychiatric disorders [reviewed in Valentino et al., 2013].
The consequences of such differences between sexes have not
been explored explicitly in AD, thus presenting an extensive gap in
our current understanding of the clinical application of drugs used
to treat non-cognitive symptoms of AD, and how these differences
may inform future therapeutic approaches. It is possible that
mood altering drugs such as anti-depressants could have protec-
tive effects on the progression of AD (Aboukhatwa et al., 2010).
While CRFR1 antagonists have, so far, been unsuccessful in treat-
ing mood and anxiety disorders (Aubry, 2013), it would be of
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beneﬁt in preclinical or early stage AD patients, particularly
females.
11. NE as a modulator of neuroinﬂammation in AD
AD exhibits an inﬂammatory component, which is evidenced in
both post mortem brain tissue, as well as a vast array of preclinical
studies in the literature. Several chemokines and chemokine re-
ceptors known to play a role in communicating signals during in-
ﬂammatory responses have been found to be up-regulated in the
AD brain (Heneka, 2006). Cultured astrocytes and microglia from
rapid autopsy of AD patients show increased levels of IL-8, MCP-1,
CCR3 and CCR5 (Heneka, 2006). AD post mortem brain tissue
analysis reveals an abundance of activated microglia that are IL-1b
immunopositive and almost exclusively associated with amyloid
deposits in the AD brain (Akiyama et al., 1993; Grifﬁn et al., 1995).
Further, the expression of the inducible form of nitric oxide syn-
thase (NOS2) has been described in neurons and astrocytes of the
AD brain (Heneka and Feinstein, 2001). These results have served as
the basis for numerous preclinical studies to further explore and
provide a mechanistic basis for the role of inﬂammation in AD. One
factor that may contribute to these inﬂammatory alterations in the
AD brain is oxidative stress, reﬂected in the oxidation of brain
lipids, carbohydrates, proteins and DNA (Markesbery, 1999). Reac-
tive oxygen species may then stimulate the activation of tran-
scription factors such as NF-kB, which initiate the inﬂammatory
cascade (Morgan and Liu, 2011). Of particular importance, is the
ﬁnding that the LC-NE system is a critical player in mediating these
inﬂammatory responses, and that the degeneration of the LC ex-
acerbates inﬂammatory and cytotoxic insults induced by Ab. The
diversity among- NE receptors allows for an extensive inﬂuence
over the cellular environment. For example, the presence of b2AR
on astrocytes and microglia in addition to their presence on neu-
rons, enables the modulation inﬂammatory gene expression
(Feinstein et al., 2002). Importantly, bARs are present, and func-
tionally relevant, on both astrocytes and microglia in the brain
(O'Donnell et al., 2012) and are thought to play a role in modulating
Ab induced inﬂammation.
Studies of selective lesions of the LC utilizing the neurotoxin
DSP-4 have helped to establish this brain region as a potentially
important component of the inﬂammatory component of AD and as
a protective force against Ab induced cytotoxic insults that, when
depleted, leaves the central nervous system more vulnerable to AD
pathogenesis. One of the ﬁrst major studies to suggest this rela-
tionship showed that injection of Ab into the cortex of adult rats
potentiated the induction of iNOS, IL-1b, and IL-6 expression
following DSP-4 induced cell death in the LC. Further, when Abwas
co-injected with NE or the b-AR agonist isoproterenol in the cortex,
the effects on cytokine expression were attenuated (Heneka et al.,
2002). Other studies have demonstrated the ability of NE to block
the expression of MHCII, TNF-a, IL-1b and iNOS, supporting the
notion that NE acts as an anti-inﬂammatory agent (Feinstein et al.,
2002; Frohman et al., 1988). Further investigation into the role of
NE in inﬂammatory environments reveals that NE may have dual
effects on the production of cytokines and proinﬂammatory me-
diators (Hinojosa et al., 2013). For example, it has been demon-
strated that NE, through the activation of b2 AR, induces the
production of CCL2 (MCP-1), which acts to protect against excito-
toxicity by decreasing the synthesis and release of glutamate
(Madrigal et al., 2009). This is highly relevant to AD, as it has been
shown that high levels of glutamate occur in chronic degeneration
conditions, including AD (Lipton, 2005). Additionally, results from
studies using pro-inﬂammatory stimuli such as LPS, as well as Ab,
have demonstrated that the presence of such stimuli causes a largeproduction of CX3CL1, CCL2 (MCP-1), CCL7, CCL12, and CXCL16,
while NE has opposing effects, inhibiting the production of those
cytokines (Hinojosa et al., 2013). Thus, NE may be classiﬁed as a
modulator of neuroinﬂammation, having important consequences
for the pathogenesis of AD. As described above, the progressive
deterioration of the LC and concomitant decreases in NE suggest
the possibility that one of the driving forces exacerbating the ef-
fects of Ab is the loss of LC-NE inﬂuence.
12. Conclusions
Examining speciﬁc neuroanatomical structures such as the LC
and the neuronal pathways that connect them provide a context
for better understanding complex pathological processes associ-
ated with disorders such as AD. Perhaps one of the greatest
challenges to modern medicine is the complex pathology of Alz-
heimer's disease, which has been the topic of intense investigation
for over 100 years and still has no effective treatment. The syn-
thesis and release of Ab peptide is dysregulated in early stages of
AD, prior to neurodegeneration. Recent studies implicating Ab as a
modulator of neuronal excitability have signiﬁcant implications
not only at the synaptic, but also circuit levels of brain processes.
The LC is the brainstem nucleus characterized by its unique role as
the sole source of NE for the neuraxis, as well as its ability to
receive and integrate information from multiple brain regions to
orchestrate widespread changes in arousal, wakefulness, and the
stress response. A growing body of literature supports the clinical
relevance of the LC, NE and noradrenergic receptors in AD,
particularly in the dysregulation of Ab production. A synthesis of
evidence suggests that disruptions of LC excitability, likely asso-
ciated with an aberrant response to stressful stimuli, lead to sig-
niﬁcant increases in Ab deposition. Given the recently established
physiological role of Ab as a modulator of neuronal excitability,
and the ﬁnding that Ab function is a concentration-dependent
process, there is the potential that abnormal levels of Ab result
in network de-synchronization and disrupt cognition on a global
scale. Further, the presence of adrenergic receptors on neurons in
projection regions of the LC provides a cellular mechanism by
which NE may contribute to Ab production, and whose presence
on glial cells may contribute to decreased clearance of Ab
following reduction of NE levels, thus exacerbating neuro-
inﬂammatory conditions in later stages of AD. This underappre-
ciated role of the LC-NE system in AD has important implications
for potential therapeutic intervention as well as future studies.
While early or preclinical stages of AD may beneﬁt from treat-
ments aimed at reducing LC aberrant activation, possibly via tar-
geted gene therapy, later stage treatment may involve the use of
SNRIs which have the potential to promote GABAergic signaling
and stabilize the gamma frequency oscillations important for
attention and memory functions. There are already numerous
marketed compounds that directly modulate the NE system that
could be evaluated for their ability to slow the progression of AD.
There is also the possibility that retrospective analysis of AD pa-
tients treated with these compounds could provide valuable
insight and inﬂuence the direction of future clinical trials. In
addition, treatments speciﬁcally designed to stop or slow the
accumulation of Ab and degeneration of neurons in the LC could
prove to be very promising.
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